RPRX
HealthcareRoyalty Pharma plc · Biotechnology · $23B
What is Royalty Pharma plc?
Royalty Pharma plc is the largest buyer of biopharmaceutical royalties in the world, providing capital to drug developers in exchange for a share of future product revenues. Headquartered in New York City, the company has built a diversified portfolio spanning dozens of marketed and development-stage therapies.
Rather than discovering or manufacturing drugs itself, Royalty Pharma acquires royalty interests on medicines developed by others — universities, research hospitals, biotechs, and large pharmaceutical companies. When those therapies generate sales, Royalty Pharma collects a percentage of the revenue. This asset-light model means the company benefits from commercial success without bearing the full cost of clinical development. Its portfolio spans rare disease, oncology, neurology, infectious disease, hematology, and diabetes.
Royalty Pharma went public in 2020 and is headquartered in New York City, New York.
- Royalty acquisitions on marketed biopharmaceutical therapies
- Funding for development-stage drug candidates
- Partnerships with academic institutions and not-for-profit research organizations
- Collaborations with small and mid-cap biotechnology companies
- Portfolio diversification across multiple therapeutic areas
Is RPRX a Good Stock to Buy?
UQS Score rates RPRX as Good overall, reflecting a balanced profile with meaningful strengths and one notable area of concern.
The Quality and Growth pillars both register as Good, suggesting the business generates dependable cash flows and has demonstrated an ability to expand its royalty base over time. Valuation comes in as Attractive relative to the broader market, which may interest investors looking for exposure to biopharma without paying a premium multiple.
The Risk pillar is rated Weak, pointing to elevated uncertainty — likely tied to royalty concentration, drug lifecycle exposure, and the inherent unpredictability of biopharmaceutical revenues. The Moat pillar sits at Neutral, indicating competitive advantages exist but are not yet considered wide by UQS criteria.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does RPRX pay dividends?
Yes — Royalty Pharma plc pays a dividend.
Royalty Pharma pays a regular dividend, which aligns with its asset-light, cash-generative business model. Because the company collects royalty streams rather than funding large manufacturing operations, it can return capital to shareholders on a consistent basis. Income-oriented investors often view royalty-model companies as a relatively stable source of dividends within the healthcare sector.
When does RPRX report earnings?
Royalty Pharma reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
Results in recent periods have reflected the performance of the underlying royalty portfolio, with revenue tied to commercial sales of therapies across multiple therapeutic areas. Variability can occur when key royalties face patent cliffs or when development-stage candidates advance or stall in clinical trials.
For the most recent quarter's results and guidance, visit Royalty Pharma's investor relations page directly.
RPRX Price History
+38.1% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Royalty Pharma plc?
Based on Royalty Pharma plc's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
RPRX Long-term Outlook
The Growth pillar rating of Good suggests Royalty Pharma has credible pathways to expand its royalty base, driven by continued deal activity and the maturation of development-stage assets into commercial products. However, the Weak Risk pillar warrants attention — royalty streams are only as durable as the underlying drugs' market positions and patent protections. The Attractive Valuation label suggests the market may not be fully pricing in the growth potential, though risk-adjusted returns will depend heavily on portfolio composition going forward.
Growth drivers
- Ongoing acquisition of new royalties on late-stage and marketed therapies
- Maturation of development-stage candidates into revenue-generating products
- Expanding partnerships with academic institutions and emerging biotechs
Key risks
- Royalty concentration risk if key therapies face patent expiry or competition
- Elevated Risk pillar score reflecting biopharma revenue unpredictability
- Potential for deal pricing to compress returns if competition for royalties increases
RPRX vs Peers
Royalty Pharma operates in a niche corner of healthcare finance, but investors often compare it to other biopharma-adjacent companies when evaluating sector exposure.
Roivant takes an operational approach — building and spinning out drug development subsidiaries — rather than passively collecting royalties.
Moderna is a fully integrated mRNA drug developer that bears the full cost and risk of clinical development, in contrast to Royalty Pharma's asset-light royalty model.
Summit is a clinical-stage oncology company focused on developing its own pipeline, representing a higher-risk, higher-reward profile compared to royalty investing.
Frequently Asked Questions
What does Royalty Pharma do?
Royalty Pharma acquires royalty interests on biopharmaceutical therapies developed by universities, hospitals, biotechs, and large pharma companies. When those drugs generate sales, Royalty Pharma receives a percentage of the revenue. This model lets the company participate in drug commercialization without running clinical trials or manufacturing operations.
Does RPRX pay dividends?
Yes, Royalty Pharma pays a regular dividend. The company's asset-light, cash-generative royalty model supports consistent capital returns to shareholders. Investors seeking income within the healthcare sector often consider RPRX for this reason.
When does RPRX report earnings?
Royalty Pharma reports on a quarterly cadence, in line with standard US-listed company practice. For exact dates and the most recent results, check the investor relations section of the company's official website.
Is RPRX a good stock to buy?
UQS Score rates RPRX as Good overall. The Quality and Growth pillars are both rated Good, and Valuation is Attractive. The main caution is a Weak Risk pillar, reflecting the inherent uncertainty in royalty streams tied to drug lifecycles. The complete pillar breakdown is available to UQS Pro members.
Is RPRX overvalued?
The UQS Valuation pillar for RPRX is rated Attractive, suggesting the stock may be reasonably priced relative to its fundamentals compared to the broader market. Whether that represents value depends on how an investor weighs the Risk pillar concerns alongside the growth outlook.
How does RPRX compare to its competitors?
Unlike Moderna or Summit Therapeutics, which develop their own drug pipelines, Royalty Pharma does not bear direct clinical development risk. Roivant Sciences builds operating drug companies, while Royalty Pharma simply collects royalty streams. This makes RPRX a structurally different — and generally lower-volatility — way to gain biopharma exposure.
What is RPRX's market cap bracket?
Royalty Pharma is classified as a large-cap company, placing it among the more substantial publicly traded names in the healthcare and biopharma royalty space.
Who founded Royalty Pharma?
Royalty Pharma traces its origins to Pablo Legorreta, who established the royalty acquisition model in the late 1990s. The company went public in 2020. For full founding history, the company's investor relations and official filings provide detailed background.
Is RPRX a long-term quality investment?
As a long-term quality indicator, UQS rates RPRX as Good — supported by consistent cash generation and a diversified royalty portfolio. The Weak Risk pillar is the key variable to monitor over a long horizon, particularly as individual royalties mature or face generic competition. Pro members can view the full multi-pillar breakdown.
What is the main competitive advantage of Royalty Pharma?
Royalty Pharma's scale and deal experience give it preferential access to royalty transactions that smaller competitors cannot match. Its established relationships with academic institutions, research hospitals, and major pharmaceutical companies create a sourcing network that is difficult to replicate quickly.
What sector does RPRX belong to?
RPRX operates in the Healthcare sector, specifically within the biopharmaceutical royalty and financing niche. It sits at the intersection of financial services and drug commercialization, making it somewhat distinct from traditional pharma or biotech companies.
Is RPRX a growth stock or value stock?
Based on UQS pillar labels, RPRX shows characteristics of both — the Growth pillar is rated Good, indicating expansion potential, while the Valuation pillar is Attractive, suggesting it is not priced at a significant premium. It may appeal to investors looking for growth at a reasonable valuation within healthcare.
Unlock Full RPRX Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings
- ✓Access complete financial metrics and trend data
- ✓Compare RPRX against sector peers side by side
- ✓See the full risk breakdown behind the Weak Risk rating
- ✓Track valuation changes with updated quarterly data
- ✓Get the complete analyst-grade view in one dashboard
Pro Analysis
RPRX — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 9, 2026 | 56.4 | 67.8 | 49.0 | 55.7 | 25.5 | 81.7 | +1.2 |
| May 8, 2026 | 55.2 | 33.3 | 49.0 | 65.4 | 43.6 | 100.0 | -3.3 |
| May 7, 2026 | 58.5 | 68.9 | 49.0 | 65.4 | 18.1 | 88.0 | -0.1 |
| Apr 26, 2026 | 58.6 | 68.9 | 49.0 | 65.4 | 18.1 | 88.7 | +0.4 |
| Apr 19, 2026 | 58.2 | 68.9 | 49.0 | 65.4 | 18.1 | 86.1 | 0.0 |
| Apr 18, 2026 | 58.2 | 68.9 | 49.0 | 65.4 | 18.1 | 86.4 | -2.1 |
| Apr 2, 2026 | 60.3 | 68.9 | 49.0 | 65.4 | 18.1 | 100.0 | — |
RPRX — Pillar Breakdown
Quality
— 69.1/100 (25%)Royalty Pharma plc shows solid profitability with healthy returns on capital and reasonable margins.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 55.7/100 (20%)Royalty Pharma plc demonstrates healthy growth trends across revenue and earnings.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 35.0/100 (15%)Royalty Pharma plc has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 83.1/100 (15%)Royalty Pharma plc appears attractively valued relative to its earnings, cash flows, and sector peers.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 49/100 (25%)Royalty Pharma plc possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for RPRX.
Score Composition
Financial Data
More Stock Analysis
How is the RPRX UQS Score Calculated?
The UQS (Unified Quality Score) for Royalty Pharma plc is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Royalty Pharma plc's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Royalty Pharma plc is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.